Medpace Holdings Inc. (NASDAQ:MEDP) Relative Strength Index (RSI) is 79.51, with weekly volatility at 4.29% and ATR at 5.32. The MEDP stock’s 52-week price range has touched low of $58.72 and a $173.95 high. Intraday shares traded counted 0.21 million, which was -0.26% lower than its 30-day average trading volume of 212.06K. Its shares traded higher over the last trading session, gaining 0.54% on 02/12/21. The shares fell to a low of $165.90 before closing at $168.26. MEDP’s previous close was $167.35 while the outstanding shares total 35.55M. The firm has a beta of 1.42, a 12-month trailing P/E ratio of 51.24, and a growth ratio of 2.96.
Investors have identified the Diagnostics & Research company Medpace Holdings Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $5.99 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Medpace Holdings Inc. (MEDP) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 395.0 million total, with 358.4 million as their total liabilities.
Having a look at the company’s valuation, the company is expected to record 4.22 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on MEDP sounds very interesting.
Is the stock of MEDP attractive?
In related news, CFO & COO, Lab Operations, GEIGER JESSE J sold 4,000 shares of the company’s stock in a transaction that recorded on Feb 10. The sale was performed at an average price of 160.00, for a total value of 640,000. As the sale deal closes, the General Counsel & Corp. Secy., EWALD STEPHEN P now sold 10,000 shares of the company’s stock, valued at 1,554,800. Also, 10% Owner, Medpace Investors, LLC sold 26,666 shares of the company’s stock in a deal that was recorded on Jan 08. The shares were price at an average price of 140.71 per share, with a total market value of 3,752,173. Following this completion of acquisition, the President & CEO, Troendle August J. now holds 26,666 shares of the company’s stock, valued at 3,752,173. In the last 6 months, insiders have changed their ownership in shares of company stock by 20.30%.
3 out of 6 analysts covering the stock have rated it a Buy, while 3 have maintained a Hold recommendation on Medpace Holdings Inc.. 0 analysts has assigned a Sell rating on the MEDP stock. The 12-month mean consensus price target for the company’s shares has been set at $137.00.